Clinical Trial Update: Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms [Phase 1]

View source ↗

Summary

An open-label Phase I study of P276-00 in patients with advanced refractory cancers has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• P276-00 (P276-00)

Snippet

Sponsor: Piramal Enterprises Limited | Conditions: Neoplasm | Phase 1 | Status: COMPLETED